Holen Sie sich die Stockscreener-App
163.23
2.02%
2.9836
Schlusskurs vom Vortag:
$160.25
Offen:
$161.31
24-Stunden-Volumen:
129.20K
Relative Volume:
0.12
Marktkapitalisierung:
$9.90B
Einnahmen:
$4.09B
Nettoeinkommen (Verlust:
$-404.84M
KGV:
-24.19
EPS:
-6.7469
Netto-Cashflow:
$1.24B
1W Leistung:
-5.58%
1M Leistung:
+0.75%
6M Leistung:
+46.49%
1J Leistung:
+35.97%
1-Tages-Spanne:
$161.31
$165.64
1-Wochen-Bereich:
$156.95
$175.80
52-Wochen-Spanne:
$95.49
$182.99
Jazz Pharmaceuticals Plc Stock (JAZZ) Company Profile
Firmenname
Jazz Pharmaceuticals Plc
Sektor
Branche
Telefon
353-1-634-7800
Adresse
FIFTH FLOOR, WATERLOO EXCHANGE, DUBLIN
Vergleichen Sie JAZZ mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
JAZZ
Jazz Pharmaceuticals Plc
|
163.00 | 9.74B | 4.09B | -404.84M | 1.24B | -6.7469 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.36 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
811.17 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
407.74 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
811.36 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.32 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Jazz Pharmaceuticals Plc Stock (JAZZ) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Herabstufung | UBS | Buy → Neutral |
| 2025-07-15 | Eingeleitet | Deutsche Bank | Buy |
| 2025-03-07 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-26 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-02-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-12-12 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-06-05 | Eingeleitet | Goldman | Buy |
| 2024-01-03 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-11-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Mkt Perform |
| 2023-06-12 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2022-12-09 | Hochstufung | Goldman | Neutral → Buy |
| 2022-06-14 | Eingeleitet | UBS | Buy |
| 2022-04-06 | Herabstufung | Goldman | Buy → Neutral |
| 2021-11-19 | Fortgesetzt | Goldman | Buy |
| 2021-10-07 | Fortgesetzt | Jefferies | Buy |
| 2021-10-05 | Eingeleitet | Citigroup | Buy |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-05-19 | Fortgesetzt | JP Morgan | Overweight |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2021-02-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-01-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-16 | Eingeleitet | UBS | Buy |
| 2020-11-03 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-09 | Bestätigt | H.C. Wainwright | Buy |
| 2020-09-14 | Herabstufung | Goldman | Neutral → Sell |
| 2020-09-14 | Fortgesetzt | JP Morgan | Overweight |
| 2020-08-06 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-07-28 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-07-23 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-04-06 | Eingeleitet | Jefferies | Buy |
| 2020-03-12 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2020-01-08 | Eingeleitet | Goldman | Neutral |
| 2019-08-21 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-03-20 | Eingeleitet | SunTrust | Buy |
| 2018-12-14 | Eingeleitet | Wolfe Research | Peer Perform |
| 2018-11-08 | Bestätigt | B. Riley FBR | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-07-11 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2018-03-23 | Bestätigt | H.C. Wainwright | Neutral |
| 2018-03-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
Alle ansehen
Jazz Pharmaceuticals Plc Aktie (JAZZ) Neueste Nachrichten
Jazz Pharmaceuticals stock price target raised to $263 from $247 at BofA - Investing.com UK
Why Jazz Pharmaceuticals plc stock remains resilient2025 Earnings Impact & Daily Chart Pattern Signals - ulpravda.ru
What sentiment indicators say about Jazz Pharmaceuticals plc stockJuly 2025 WrapUp & Technical Confirmation Trade Alerts - ulpravda.ru
Jazz pharmaceuticals appoints Thomas Riga as chief business officer By Investing.com - Investing.com South Africa
Jazz Pharmaceuticals names Thomas Riga as Chief Business Officer - StreetInsider
Jazz Pharmaceuticals Appoints Thomas Riga as Chief Business Officer, Effective January 1, 2026 - MarketScreener
Should I hold or sell Jazz Pharmaceuticals plc stock in 2025Weekly Trend Summary & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
A Look At Jazz Pharmaceuticals (JAZZ) Valuation After Positive Ziihera Phase 3 Gastroesophageal Cancer Results - simplywall.st
Is Jazz Pharmaceuticals plc stock positioned well for digital economyInstitutional Holding Changes & Free Stop-Loss Planning for Your Portfolio - ulpravda.ru
Why Is Jazz Pharmaceuticals Stock Trading Higher Today?Jazz Pharmaceuticals (NASDAQ:JAZZ) - Benzinga
Jazz’s Ziihera Stakes Claim As Frontline Choice In HER2+ Gastroesophageal Cancer - Citeline News & Insights
Jazz Pharmaceuticals stock shows promise with positive Phase 3 data By Investing.com - Investing.com Nigeria
Jazz Pharma stock falls after lowered full year guidance - MSN
Jazz boasts of first-line Ziihera data in gastroesophageal cancers - MSN
Jazz Pharmaceuticals stock falls after Phase 3 trial results By Investing.com - Investing.com South Africa
Baird reiterates Underperform rating on Jazz Pharmaceuticals stock at $209 By Investing.com - Investing.com Nigeria
Jazz Pharmaceuticals' Ziihera Therapy Significantly Extends Survival in GEA Patients - Intellectia AI
Jazz Pharmaceuticals announce positive efficacy from Ziihera phase 3 trial - MarketScreener
Jazz’s Ziihera shows unprecedented survival benefit in gastric cancer By Investing.com - Investing.com UK
Ziihera® (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit - GlobeNewswire Inc.
Jazz Pharmaceuticals stock rating reiterated at Outperform by RBC Capital - Investing.com Nigeria
Psychedelic Drugs Market to Reach USD 9.20 Billion by 2033 | CAGR - openPR.com
Volume Summary: Will Jazz Pharmaceuticals plc stock deliver long term returnsDividend Hike & Consistent Income Trade Recommendations - moha.gov.vn
The Truth About Jazz Pharmaceuticals: Is Wall Street Sleeping On This Quiet Game-Changer? - AD HOC NEWS
How Jazz Pharmaceuticals Plc (JAZZ) Affects Rotational Strategy Timing - Stock Traders Daily
Jazz Pharmaceuticals stock falls after Phase 3 trial results - Investing.com
Reflecting On Pharmaceuticals Stocks’ Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) - Yahoo Finance
Corient Private Wealth LLC Cuts Stock Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Reflecting On Pharmaceuticals Stocks' Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ) - Finviz
Pacer Advisors Inc. Sells 194,639 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Assessing Jazz Pharmaceuticals (JAZZ) Valuation After a Strong Year-to-Date Share Price Rally - simplywall.st
Jazz Pharmaceuticals (FRA:J7Z) EV-to-OCF : 9.16 (As of Dec. 21, 2025) - GuruFocus
Update Report: What sentiment indicators say about Jazz Pharmaceuticals plc stockIPO Watch & Risk Controlled Daily Trade Plans - moha.gov.vn
JAZZ SEC FilingsJazz Pharmaceuticals Plc 10-K, 10-Q, 8-K Forms - Stock Titan
211,185 Shares in Jazz Pharmaceuticals PLC $JAZZ Acquired by Wedge Capital Management L L P NC - MarketBeat
Published on: 2025-12-21 12:21:40 - Улправда
Volume Summary: Is Jazz Pharmaceuticals plc stock positioned well for digital economy2025 Fundamental Recap & AI Based Buy/Sell Signal Reports - ulpravda.ru
Perpetual Ltd Reduces Stock Position in Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Jazz Pharmaceuticals (MEX:JAZZ) EV-to-OCF : 8.83 (As of Dec. 19, 2025) - GuruFocus
Jazz Pharmaceuticals (MIL:1JAZZ) EV-to-FCF : 10.20 (As of Dec. 19, 2025) - GuruFocus
Jazz Pharmaceuticals (MIL:1JAZZ) EV-to-OCF : 9.11 (As of Dec. 19, 2025) - GuruFocus
Resistance Check: Why Jazz Pharmaceuticals plc stock remains resilientChart Signals & Weekly Chart Analysis and Trade Guides - DonanımHaber
Is Jazz Pharmaceuticals plc stock cheap compared to fundamentalsBear Alert & Expert Approved Trade Ideas - Улправда
Is It Too Late To Consider Jazz Pharmaceuticals After Its Strong 2024 Share Price Rally? - Yahoo Finance
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Clinical momentum lifts biopharma stocks into year-end - BioWorld MedTech
3 Reasons JAZZ is Risky and 1 Stock to Buy Instead - Barchart.com
Jazz Pharmaceuticals to Participate in Upcoming Investor Events - PR Newswire
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Texas Permanent School Fund Corp - MarketBeat
Jazz Pharmaceuticals (JAZZ): Valuation Check After Positive Ziihera and Epidiolex Clinical Updates Boost Investor Interest - simplywall.st
How Fresh Epidiolex and Ziihera Data Accepted at Key Meetings At Jazz Pharmaceuticals (JAZZ) Has Changed Its Investment Story - simplywall.st
Finanzdaten der Jazz Pharmaceuticals Plc-Aktie (JAZZ)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):